Cleveland BioLabs Strengthens Clinical Development Team

Cleveland BioLabs Strengthens Clinical Development Team

BUFFALO, N.Y., April 8, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc.
(Nasdaq:CBLI) announced today the appointment of key clinical development and
regulatory affairs executives to optimally position the company for successful
development of its drug candidates. Jean Viallet, M.D., has joined the Company
as Chief Development Officer, reporting to the Chief Executive Officer, and
will be responsible for overseeing CBLI's clinical strategy, trials and
operations, regulatory affairs and preclinical development.The Company also
announced the appointment of Gillian Miller, Ph.D., as Senior Director of
Regulatory Affairs and Judith Schnyder, MBA as Director of Clinical

Dr. Viallet brings more than 20 years of experience as a medical oncologist
and senior executive at both large and small pharmaceutical companies.Most
recently, Dr. Viallet established Viallet Oncology Consulting, LLC after
serving as the Chief Medical Officer of Precision Therapeutics, Inc. Prior to
this he guided clinical and preclinical development at Gemin X
Pharmaceuticals, Inc., as their Executive Vice President and Chief Medical
Officer, culminating in a successful strategic acquisition of Gemin X by
Cephalon, Inc.Before joining Gemin X, Dr. Viallet held senior clinical
oncology development positions at GlaxoSmithKline PLC and Sanofi.He has
extensive experience with all phases of drug development and has been involved
in multiple successful Investigational New Drug applications, New Drug
Applications, Biologics License Applications, European Medicines Agency
submissions and U.S. Food and Drug Administration Advisory Committees.Dr.
Viallet has also served in several clinical and academic posts at Hospital
Notre Dame, Montreal General Hospital, McGill University and the Universite de

Dr. Viallet noted, "As a clinical oncologist and scientist, I am grateful for
the opportunity to guide CBLI's drug candidates derived from world-class
science into established therapeutic advances for cancer patients and victims
of potentially lethal radiation exposure.The company's spirit of innovation,
their commitment to developing breakthrough treatments for oncology and acute
radiation syndrome and the promising 'trial-ready' drugs in their pipeline are
what attracted me to CBLI."

Dr. Miller's 15 years of regulatory affairs and clinical development
experience in both the U.S. and Europe give her significant insight and
experience in product registration and development strategies for novel and
marketable small molecules and biologics for oncology and other therapeutic
areas.Most recently, Dr. Miller worked as a consultant with SciLucent, LLC,
providing regulatory, product development, and project management services for
small and large companies with agents at various stages of readiness for
approval in the U.S. and Europe.From 2004 to 2006, she was Associate Director
of Regulatory Affairs at MedImmune and prior to that served in regulatory
affairs roles at Shire Pharmaceutical Development and the Otsuka Maryland
Research Institute.Dr. Miller started her career as a scientist at Becton
Dickinson Technologies and then Cato Research Ltd. and was a Post-doctoral
Fellow at Johns Hopkins Medical School.

Ms. Schnyder is a 15 year clinical research veteran with extensive oncology
trials experience gained through a variety of positions at biotechnology and
pharmaceutical companies and with a Clinical Research Organization.Most
recently, Schnyder consulted on Phase I–IV oncology trials through her own
firm, JAS Clinical Consulting, LLC.From 2008 to 2011, she worked alongside
Dr. Viallet at Gemin X Pharmaceuticals, Inc., as their Senior Clinical
Development Manager, where she managed a global phase I/II Small Cell Lung
Cancer trial in 10 countries and a phase II Non-Small Cell Lung Cancer trial
testing a novel bcl-2 inhibitor.Ms. Schnyder started her career at Medimmune
Oncology, Inc., then worked at Cephalon, Inc. and Pharmanet, Inc. and was a
Lead Clinical Oncology Development Scientist for GlaxoSmithKline PLC from 2002
to 2005.

Yakov Kogan, Ph.D., MBA, Chief Executive Officer commented, "We are very
excited to welcome our new team members.They have extensive expertise in
oncology clinical development, and a track record of success.We believe that
the team's decades of experience and their prior leadership appointments will
enable us to form and execute a strong trial strategy."

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging
deep mechanistic understanding of the cell death process, apoptosis, to
develop a robust pipeline of compounds primarily focused on oncology
applications and mitigation of radiation injury. The Company's lead compound
is being developed as both a radiation countermeasure and a cancer treatment.
The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs,
Inc., and strategic relationships with the Cleveland Clinic, Roswell Park
Cancer Institute, the Children's Cancer Institute Australia and the Armed
Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs,
Inc., please visit the Company's website at

This press release contains certain forward-looking information about
Cleveland BioLabs that is intended to be covered by the safe harbor for
"forward-looking statements" provided by the Private Securities Litigation
Reform Act of 1995, as amended. Forward-looking statements are statements that
are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"
"will," "may," "anticipate(s)" and similar expressions are intended to
identify forward-looking statements. These statements include, but are not
limited to, statements regarding our ability to successfully obtain regulatory
approval for our therapeutic product candidates; statements regarding our
ability to successfully develop and commercialize our therapeutic products;
our ability to expand our long-term business opportunities; the conduct and
results of our various clinical trials; and future performance. All of such
statements are subject to certain risks and uncertainties, many of which are
difficult to predict and generally beyond the control of the Company, that
could cause actual results to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements.

These factors include, among others, the Company's inability to obtain
regulatory approval in a timely manner or at all; the Company's failure to
develop new products; the Company's collaborative relationships and the
financial risks related thereto; the risks inherent in the early stages of
drug development and in conducting clinical trials. Some of these factors
could cause future results to materially differ from the recent results or
those projected in forward-looking statements.See also the "Risk Factors" and
"Forward-Looking Statements" described in the Company's periodic filings with
the Securities and Exchange Commission.

Rachel Levine, Director Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439

Cleveland BioLabs, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.